Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2026-01-10 @ 3:45 PM
Study NCT ID:
NCT06622005
Status:
RECRUITING
Last Update Posted:
2025-04-16
First Post:
2024-09-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-04-10
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-04-10
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-30
First Submit QC Date:
None
Study First Post Date:
2024-10-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-15
Last Update Post Date:
2025-04-16
Last Update Post Date Type:
ACTUAL